sanofi-aventis to acquire BiPar

sanofi-aventis Group (Euronext:SAN; NYSE:SNY) will acquire cancer company BiPar Sciences Inc. (Brisbane, Calif.) for up to $500 million in cash, which includes an undisclosed upfront payment and milestones related to development of BSI-201, BiPar's lead compound. BSI-201 is a poly(ADP-ribose) polymerase (PARP) inhibitor that is in Phase II testing for various cancers, including triple-negative breast cancer (TNBC) and ovarian cancer. The deal is expected to close this quarter. ...